Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection

Emerging Microbes and Infections

Volumn 8, Issue 1, 2019, Pages 760-772

  Jia, Wenxu ^a   Channappanavar, Rudragouda ^b,c   Zhang, Chao ^d,e   Li, Mingxi ^a   Zhou, Haixia ^f   Zhang, Shuyuan ^f   Zhou, Panpan ^a   Xu, Jiuyang ^a   Shan, Sisi ^a   Shi, Xuanling ^a   Wang, Xinquan ^f   Zhao, Jincun ^g   Zhou, Dongming ^e   Perlman, Stanley ^b,g   Zhang, Linqi ^a  

^a Tsinghua University   (China)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^e INSTITUTE PASTEUR OF SHANGHAI   (China)

^f TSINGHUA UNIVERSITY   (China)

^g GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

chimpanzee adenoviral vector; intranasal immunization; MERS CoV vaccine; monoclonal antibody; receptor binding domain (RBD)

Indexed keywords

ADENOVIRUS VACCINE; ANTISERUM; GLYCOPROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRAL PROTEIN; VITRONECTIN; CORONAVIRUS SPIKE GLYCOPROTEIN; DRUG CARRIER; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ABSORPTION; ADENOVIRIDAE; ADENOVIRUS 68; ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; EPITOPE MAPPING; GENE KNOCK-IN; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; MIDDLE EAST RESPIRATORY SYNDROME; MOUSE; MOUSE MODEL; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; SEROTYPE; SURVIVAL; T LYMPHOCYTE; VIRUS LOAD; VIRUS RECOMBINANT; ANIMAL; BLOOD; CORONAVIRUS INFECTION; GENETICS; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SURVIVAL ANALYSIS; TRANSGENIC ANIMAL; TREATMENT OUTCOME;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; DRUG CARRIERS; HUMANS; IMMUNIZATION, PASSIVE; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 85066487976     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1080/22221751.2019.1620083     Document Type: Article

References (65)

1. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. doi:10.1056/NEJMoa1211721.
2. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China. Lancet. 2003;362:1353–1358. doi: 10.1016/S0140-6736(03)14630-2
3. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV); 2019 http://www.who.int/emergencies/mers-cov/en/
4. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV); 2017 http://www.who.int/emergencies/mers-cov/en/
5. Wilder-Smith A, Teleman MD, Heng BH, et al. Asymptomatic SARS coronavirus infection among healthcare workers, Singapore. Emerg Infect Dis. 2005;11:1142–1145. doi: 10.3201/eid1107.041165
6. Song Y-j, Yang JS, Yoon HJ, et al. Asymptomatic Middle East Respiratory syndrome coronavirus infection using a serologic survey in Korea. Epidemiol Health. 2018;40:e2018014. doi:10.4178/epih.e2018014.
7. Azhar EI, El-Kafrawy SA, Farraj SA, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014;370:2499–2505. doi:10.1056/NEJMoa1401505.
8. Haagmans BL, Al Dhahiry SHS, Reusken CBEM, et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis. 2014;14:140–145. doi:10.1016/S1473-3099(13)70690-X.
9. Du L, Yang Y, Zhou Y, et al. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017;21:131–143. doi:10.1080/14728222.2017.1271415.
10. Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226–236. doi:10.1038/nrmicro2090.
11. Masters PS., The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193–292. doi:10.1016/S0065-3527(06)66005-3.
12. Graham RL, Donaldson EF, Baric RS., A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013;11:836–848. doi:10.1038/nrmicro3143.
13. Weiss SR, Navas-Martin S., Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005;69:635–664. doi:10.1128/MMBR.69.4.635-664.2005.
14. Li F., Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol. 2015;89:1954–1964. doi:10.1128/JVI.02615-14.
15. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254. doi:10.1038/nature12005.
16. Wang N, Shi X, Jiang L, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986–993. doi:10.1038/cr.2013.92.
17. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500:227–231. doi:10.1038/nature12328.
18. Ohnuma K, Haagmans BL, Hatano R, et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol. 2013;87:13892–13899. doi:10.1128/JVI.02448-13.
19. Rabaan AA, Alahmed SH, Bazzi AM, et al. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol. 2017;66:1261–1274. doi:10.1099/jmm.0.000565.
20. Ying T, Li H, Lu L, et al. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect. 2015;17:142–148. doi:10.1016/j.micinf.2014.11.008.
21. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med. 2014;6:234ra59. doi:10.1126/scitranslmed.3008140.
22. Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014;88:7796–7805. doi:10.1128/JVI.00912-14.
23. Niu P, Zhang S, Zhou P, et al. Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient. J Infect Dis. 2018;218:1249–1260. doi:10.1093/infdis/jiy311.
24. Zhao G, He L, Sun S, et al. A novel nanobody targeting Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV. J Virol. 2018;92:e00837-18. doi:10.1128/JVI.00837-18.
25. Stalin Raj V, Okba NMA, Gutierrez-Alvarez J, et al. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. Sci Adv. 2018;4:eaas9667. doi:10.1126/sciadv.aas9667.
26. Tang XC, Agnihothram SS, Jiao Y, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA. 2014;111:E2018–E2026. doi:10.1073/pnas.1402074111.
27. Pascal KE, Coleman CM, Mujica AO, et al. Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA. 2015;112:8738–8743. doi:10.1073/pnas.1510830112.
28. Yu X, Zhang S, Jiang L, et al. Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci Rep. 2015;5:13133. doi:10.1038/srep13133.
29. Zhang S, Zhou P, Wang P, et al. Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein. Cell Rep. 2018;24:441–452. doi:10.1016/j.celrep.2018.06.041.
30. Kaufmann SH, McElrath MJ, Lewis DJ, et al. Challenges and responses in human vaccine development. Curr Opin Immunol. 2014;28:18–26. doi:10.1016/j.coi.2014.01.009.
31. Du L, Tai W, Zhou Y, et al. Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016;15:1123–1134. doi:10.1586/14760584.2016.1167603.
32. Du L, Jiang S., Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin Biol Ther. 2015;15:1647–1651. doi:10.1517/14712598.2015.1092518.
33. Zhang N, Jiang S, Du L., Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014;13:761–774. doi:10.1586/14760584.2014.912134.
34. Perlman S, Vijay R., Middle East respiratory syndrome vaccines. Int J Infect Dis. 2016;47:23–28. doi:10.1016/j.ijid.2016.04.008.
35. Wirblich C, Coleman CM, Kurup D, et al. One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus. J Virol. 2017;91:e02040-16. doi:10.1128/JVI.02040-16.
36. Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7:301ra132. doi:10.1126/scitranslmed.aac7462.
37. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA. 2014;111:4970–4975. doi:10.1073/pnas.1323279111.
38. Modjarrad K., MERS-CoV vaccine candidates in development: the current landscape. Vaccine. 2016;34:2982–2987. doi:10.1016/j.vaccine.2016.03.104.
39. Li K, Wohlford-Lenane CL, Channappanavar R, et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci USA. 2017;114:E3119–E3128. doi:10.1073/pnas.1619109114.
40. Roy S, Gao G, Lu Y, et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther. 2004;15:519–530. doi:10.1089/10430340460745838.
41. Farina SF, Gao G-p, Xiang ZQ, et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001;75:11603–11613. doi:10.1128/JVI.75.23.11603-11613.2001.
42. Vitelli A, Folgori A, Scarselli E, et al. Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane. Expert Rev Vaccines. 2017;16:1241–1252. doi:10.1080/14760584.2017.1394842.
43. O'Hara GA, Duncan CJA, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012;205:772–781. doi:10.1093/infdis/jir850.
44. Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1. doi:10.1126/scitranslmed.3003155.
45. Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014;22:668–674. doi:10.1038/mt.2013.284.
46. Ferguson NM, Van Kerkhove MD., Identification of MERS-CoV in dromedary camels. Lancet Infect Dis. 2014;14:93–94. doi:10.1016/S1473-3099(13)70691-1.
47. Reusken CB, Haagmans BL, Müller MA, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013;13:859–866. doi:10.1016/S1473-3099(13)70164-6.
48. Cotten M, Watson SJ, Kellam P, et al. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet. 2013;382:1993–2002. doi:10.1016/S0140-6736(13)61887-5.
49. Hayton EJ, Rose A, Ibrahimsa U, et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus Ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One. 2014;9:e101591. doi:10.1371/journal.pone.0101591.
50. Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector ebola vaccine. N Engl J Med. 2017;376:928–938. doi:10.1056/NEJMoa1410863.
51. De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16:311–320. doi:10.1016/S1473-3099(15)00486-7.
52. Borthwick N, Ahmed T, Ondondo B, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther. 2014;22:464–475. doi:10.1038/mt.2013.248.
53. Green CA, Scarselli E, Sande CJ, et al. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med. 2015;7:300ra126. doi:10.1126/scitranslmed.aac5745.
54. Munster VJ, Wells D, Lambe T, et al. Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. NPJ Vaccines. 2017;2:28. doi:10.1038/s41541-017-0029-1.
55. Alharbi NK, Padron-Regalado E, Thompson CP, et al. Chadox1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017;35:3780–3788. doi:10.1016/j.vaccine.2017.05.032.
56. Hodgson SH, Ewer KJ, Bliss CM, et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2015;211:1076–1086. doi:10.1093/infdis/jiu579.
57. Tutykhina IL, Logunov DY, Shcherbinin DN, et al. Development of adenoviral vector-based mucosal vaccine against influenza. J Mol Med (Berl). 2011;89:331–341. doi:10.1007/s00109-010-0696-0.
58. Holmgren J, Czerkinsky C., Mucosal immunity and vaccines. Nat Med. 2005;11:S45–S53. doi:10.1038/nm1213.
59. van den Brand JM, Smits SL, Haagmans BL., Pathogenesis of Middle East respiratory syndrome coronavirus. J Pathol. 2015;235:175–184. doi:10.1002/path.4458.
60. Nassar MS, Bakhrebah MA, Meo SA, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;22:4956–4961. doi:10.26355/eurrev_201808_15635.
61. Zhou N, Zhang Y, Zhang JC, et al. The receptor binding domain of MERS-CoV: the Dawn of vaccine and treatment development. J Formos Med Assoc. 2014;113:143–147. doi:10.1016/j.jfma.2013.11.006.
62. Zhang N, Tang J, Lu L, et al. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res. 2015;202:151–159. doi:10.1016/j.virusres.2014.11.013.
63. Zhang N, Channappanavar R, Ma C, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016;13:180–190. doi:10.1038/cmi.2015.03.
64. Yang Y, Deng Y, Wen B, et al. The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. Viral Immunol. 2014;27:543–550. doi:10.1089/vim.2014.0080.
65. Lan J, Yao Y, Deng Y, et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine. 2015;2:1438–1446. doi:10.1016/j.ebiom.2015.08.031.